Published in J Pharmacol Exp Ther on February 01, 1967
Use and abuse of over-the-counter analgesic agents. J Psychiatry Neurosci (1998) 1.16
Paracetamol and phenacetin. Drugs (1986) 0.99
A possible link between sensation-seeking status and positive subjective effects of oxycodone in healthy volunteers. Pharmacol Biochem Behav (2009) 0.82
Sedative properties of simple analgesics. Br J Pharmacol (1969) 0.75
What we don't know about over-the-counter analgesics. J Psychiatry Neurosci (1997) 0.75
Adverse drug reactions. A critical review. JAMA (1975) 5.27
Adverse drug reactions-a matter of opinion. Clin Pharmacol Ther (1976) 4.07
Cost of innovation in the pharmaceutical industry. J Health Econ (1991) 4.01
Drug prescribing and use in an American community. Ann Intern Med (1972) 3.55
Obtaining informed consent. Form or substance. Arch Intern Med (1969) 2.52
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther (1995) 2.41
Oral contraceptive patient information. A questionnaire study of attitudes, knowledge, and preferred information sources. JAMA (1976) 2.34
Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther (1983) 2.16
Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther (1977) 2.09
Differential education concerning therapeutics and resultant physician prescribing patterns. J Med Educ (1972) 2.00
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
A study of hospital staff attitudes concerning the comparative merits of antibiotics. Clin Pharmacol Ther (1971) 1.88
The relationship between physician characteristics and prescribing appropriateness. Med Care (1972) 1.83
Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther (1984) 1.59
The Helsinki Declaration: timeless guide or irrelevant anachronism? J Clin Psychopharmacol (1995) 1.58
Commentary: Patient package inserts. I. Nature, notions, and needs. Clin Pharmacol Ther (1975) 1.53
Prescribing patterns of physicians. J Chronic Dis (1969) 1.44
Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther (1974) 1.41
The rate of development of new drugs in the United States, 1963 through 1975. Clin Pharmacol Ther (1978) 1.41
Over-the-counter hypnotics and chronic insomnia in the elderly. J Clin Psychopharmacol (1995) 1.40
The interaction between bleomycin and radiation on cell survival and DNA damage in mammalian cell cultures. Int J Radiat Oncol Biol Phys (1985) 1.36
Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease. Ann N Y Acad Sci (1971) 1.36
Free-living volunteer's motivations and attitudes toward pharmacologic studies in man. Clin Pharmacol Ther (1977) 1.36
Attitudes of patients, housestaff, and nurses toward postoperative analgesic care. Anesth Analg (1983) 1.35
Compliance as a determinant of serum digoxin concentration. JAMA (1973) 1.34
Drug interaction in the field of analgesic drugs. Proc R Soc Med (1965) 1.30
Problems in publication of clinical trial methodology. Clin Pharmacol Ther (1979) 1.26
The Halcion story: trial by media. Lancet (1980) 1.24
Analgesic methodology: a brief history and commentary. J Clin Pharmacol (1980) 1.14
Analysis of narcotic analgesic usage in the treatment of postoperative pain. JAMA (1983) 1.13
Clinical trials and tribulations. Arch Intern Med (1974) 1.11
Variations in interpretation of prescription instructions. The need for improved prescribing habits. JAMA (1974) 1.10
Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest (1971) 1.07
The impact of scientific models on clinical psychopharmacology: a pharmacologist's view. Semin Psychiatry (1972) 1.06
Phenformin and lactic acidosis. Clin Pharmacol Ther (1966) 1.06
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther (1992) 1.02
Fault and default. N Engl J Med (1973) 0.97
Report of a workshop on fixed-ratio drug combinations. Eur J Clin Pharmacol (1975) 0.97
Hepatic microsomal drug oxidation and electron transport in newborn infants. J Pediatr (1974) 0.96
Correlates of physicians' prescribing behavior. Inquiry (1972) 0.96
A controlled trial of urethane treatment in multiple myeloma. Blood (1966) 0.95
L-dopa treatment failure: explanation and correction. Br Med J (1970) 0.95
How reliable are enteric-coated aspirin preparations? Clin Pharmacol Ther (1966) 0.95
Editorial: How useful are serum digitalis measurements? N Engl J Med (1976) 0.94
Drug discovery and introduction: regulation and overregulation. Clin Pharmacol Ther (1976) 0.94
Arcus not so senilis. Ann Intern Med (1968) 0.93
Demystifying central review boards: current options and future directions. IRB (2002) 0.93
The hypnotic efficacy of doxylamine. Clin Pharmacol Ther (1967) 0.93
Placebos and controlled trials under attack. Eur J Clin Pharmacol (1979) 0.91
Hypnotic drugs. N Engl J Med (1972) 0.91
Combined clinical and metabolic study of the effects of alpha-methyldopa on hypertensive patients. Circulation (1966) 0.91
Editorial: A plea for the "naturalistic" study of medicines. Eur J Clin Pharmacol (1974) 0.90
The management of pain. Drugs (1986) 0.89
A study of cross-tolerance to circulatory effects of organic nitrates. Clin Pharmacol Ther (1967) 0.89
Tolerance to drug-induced writhing in mice. J Pharmacol Exp Ther (1968) 0.89
Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry (1976) 0.89
The safety and efficacy of the estrogen patient package insert. A questionnaire study. JAMA (1979) 0.89
Hydrocarbon pneumonitis. Pediatrics (1974) 0.89
The role of the research-based pharmaceutical industry in medical progress in the United States. J Clin Pharmacol (1993) 0.88
Analgesic activity of oral naproxen in patients with postoperative pain. Scand J Rheumatol Suppl (1973) 0.88
Discovering adverse drug reactions. JAMA (1983) 0.88
A comparison of the effects of orally administered barbiturate salts and barbiturate acids on human psychomotor performance. J Pharmacol Exp Ther (1968) 0.88
Development of hepatic microsomal drug-oxidizing enzymes in immature male and female rats. J Pharmacol Exp Ther (1972) 0.88
The pharmaceutical revolution: its impact on science and society. Science (1969) 0.87
Current medical practice and the Food and Drug Administration. Some evidence for the existing gap. JAMA (1974) 0.87
Drug concentrations in neuropsychiatry. Introduction: the rational use of plasma drug levels in clinical medicine. Ciba Found Symp (1979) 0.87
A comparison of drug product information in four national compendia. Clin Pharmacol Ther (1983) 0.86
Effect of monoamine oxidase inhibitors on the N-demethylation and hydrolysis of meperidine. Biochem Pharmacol (1970) 0.86
Sounding Boards. Historical controls: the practitioner's clinical trials. N Engl J Med (1982) 0.86
The role of benzodiazepines in nonpsychiatric medical practice. Am J Psychiatry (1977) 0.85
Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. Pharmacoeconomics (1995) 0.84
Correlation of dextroamphetamine excretion and drug response in hyperkinetic children. J Nerv Ment Dis (1968) 0.84
The quantification of pain: an analysis of words used to describe pain and analgesia in clinical trials. Clin Pharmacol Ther (1982) 0.84
The effect of 5-hydroxytryptamine on the cotton pellet local inflammatory response in the rat. J Exp Med (1967) 0.83
Conjoint clinic on pain and analgesia. J Chronic Dis (1966) 0.83
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem Pharmacol (1971) 0.83
Randomized clinical trials. N Engl J Med (1976) 0.82
Commentary. The normal volunteer in clinical investigation: how rigid should selection criteria be? Clin Pharmacol Ther (1975) 0.82
Trends in drug development: the 1985-86 new drug approvals. J Clin Pharmacol (1987) 0.82
New indications for already-approved drugs: an analysis of regulatory review times. J Clin Pharmacol (1991) 0.81
Effect of naloxone on the analgesic activity of methadone in a 1:10 oral combination. Time and cost of flirting with the null hypothesis in tests of equivalence. Clin Pharmacol Ther (1974) 0.81
New drug applications: how long to gain approval? Clin Pharmacol Ther (1985) 0.81
Digoxin-prescribing. Mostly good news. JAMA (1979) 0.81
Heroin: a medical "me too". N Engl J Med (1981) 0.80
New drug development in the United States from 1963 to 1990. Clin Pharmacol Ther (1991) 0.80
Characteristics and attitudes of physicians associated with the prescribing of chloramphenicol. HSMHA Health Rep (1971) 0.80
New drug development in the United States, 1963 through 1984. Clin Pharmacol Ther (1988) 0.79
Does the public need protection from itself? Clin Ther (1987) 0.79
Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J Lab Clin Med (1972) 0.79
The effect of phenelzine and tranylcypromine on the degradation of meperidine. J Pharmacol Exp Ther (1970) 0.79
Reduction of anxiety and postoperative analgesic requirements by audiovisual instruction. Lancet (1983) 0.78
Correlation between plasma concentrations of chlorpromazine and clinical response. Commun Psychopharmacol (1978) 0.78
Dose-related sleep disturbances induced by coffee and caffeine. Clin Pharmacol Ther (1977) 0.77
The placebo effect. J Allergy Clin Immunol (1986) 0.77
Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991. Clin Pharmacol Ther (1995) 0.77
Clinical trials of drugs from the viewpoint of the academic investigator (a satire). Clin Pharmacol Ther (1975) 0.77
Metabolism of SU-13437--a new hypolipidemic drug in man. Clin Pharmacol Ther (1970) 0.77
Oral ciramadol in the treatment of postoperative pain. Clin Pharmacol Ther (1985) 0.77
Post mortem characteristics of the hepatic microsomal drug oxidising enzyme system. Chem Biol Interact (1973) 0.77